MGNX — MacroGenics, Inc.
Is MGNX overbought or oversold? Here is the current MarketMoodz read.
MacroGenics, Inc. (MGNX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $3.58. The rating moved from Strong Oversold to Oversold on October 1, 2026.
- Public ratingOversold (as of October 3, 2026)
- Last close$3.58
- Last changeMoved from Strong Oversold to Oversold on October 1, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
MacroGenics, Inc. (MGNX) is a clinical-stage biopharma with immuno-oncology and antibody-focused assets that present binary upside from trial readouts and partnerships but also carry typical small-cap biotech execution and financing risk. Current market risk-off sentiment and constrained healthcare IPO/activity reduce upside in the near term, while payer and policy pressure on drug pricing increases medium-term commercialization uncertainty. Absent a near-term positive clinical or partnership catalyst, the stock is likely to remain volatile and sensitive to funding news; a successful late-stage outcome or strategic collaboration would materially improve commercial prospects and valuation.
Key factors
- Clinical-stage pipeline with immuno-oncology and antibody programs that could generate binary, high-value catalysts (trial readouts, regulatory actions, partnerships).
- Historical ability to secure collaborations and partnerships that can de-risk development and provide non-dilutive funding or milestone revenues.
- Cash runway and balance-sheet sensitivity: small-cap biotech financing needs make equity dilution or financing deals likely if clinical timelines extend or costs rise.
- Macro and sector backdrop is risk-off (reduced IPO and speculative capital), which compresses valuations for developmental biotechs and limits near-term upside.
- Policy and payer pressure (Medicare drug-price negotiation/IRA) increase long-term pricing and access uncertainty for novel biologics, influencing commercial expectations.
- Competitive landscape in oncology and specialty biologics — larger incumbents and platform players can pressure market share, development speed, and partnering dynamics.
Risks
- Clinical trial failure or delayed readouts for lead programs, producing sharp negative re-ratings and capital access challenges.
- Need for additional capital leading to equity dilution or onerous partnership terms that reduce upside for existing shareholders.
- Regulatory setbacks or longer-than-expected approval timelines for therapeutic candidates.
- Downward pricing pressure and restricted formulary access driven by ongoing Medicare negotiation and payer cost-control measures.
- Broader market risk-off environment and low liquidity in small-cap biotech stocks exacerbating volatility and limiting buyers at higher prices.
- Manufacturing, supply chain or CMC issues that delay commercialization or complicate partnerships.
See today's live rating, score and targets
Members see the live hourly rating for MGNX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.